1-(2-(decylthio)ethyl)azacyclopentane-2-one has been researched along with lauric acid in 1 studies
| Studies (1-(2-(decylthio)ethyl)azacyclopentane-2-one) | Trials (1-(2-(decylthio)ethyl)azacyclopentane-2-one) | Recent Studies (post-2010) (1-(2-(decylthio)ethyl)azacyclopentane-2-one) | Studies (lauric acid) | Trials (lauric acid) | Recent Studies (post-2010) (lauric acid) |
|---|---|---|---|---|---|
| 12 | 0 | 0 | 921 | 38 | 343 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, H; Irie, T; Manako, T; Saita, M; Uekama, K; Yano, T | 1 |
1 other study(ies) available for 1-(2-(decylthio)ethyl)azacyclopentane-2-one and lauric acid
| Article | Year |
|---|---|
Inhibitory effect of prostaglandin E1 on laurate-induced peripheral vascular occlusive sequelae in rabbits: optimized topical formulation with beta-cyclodextrin derivative and penetration enhancer HPE-101.
Topics: Administration, Topical; Alprostadil; Animals; Cyclodextrins; Drug Carriers; Drug Combinations; Ear; Lauric Acids; Male; Ointments; Peripheral Vascular Diseases; Pyrroles; Rabbits | 1992 |